Advisory board for rare disease specialists: end-to-end scientific event support from slide design to expert consensus report
The clinical experts who matter most are not always the physicians
For this rare metabolic disorder, specialist clinicians are the primary ongoing clinical managers. They make the day-to-day treatment decisions and are often the first point of contact when patients experience management difficulties.
A brand launching a new treatment for this rare condition understood that specialist clinician alignment was critical for clinical adoption. But no structured forum existed for bringing this expert group together across markets — advisory boards in the rare disease space tended to focus on physicians.
The brand needed to convene this expert group, facilitate a structured scientific discussion, and produce a consensus document that specialists themselves would recognise as credible and practically useful.
Advisory boards in rare disease often overlook the specialists who manage patients most intensively. The clinical expert closest to the patient is not always the physician.
What we did
Measurable impact
The consensus report was delivered to all participants within 1 week of the advisory board, documenting areas of consensus across all clinical discussion topics. Several participating specialist departments adopted the report as an internal reference document for their management protocols. The brand's Medical Affairs team used the consensus document as the foundation for their HCP education programme across all participating markets.
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
From the field:
evidence & practice
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.